CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase Ib Trial of BYL719 (an α-Specific PI3K Inhibitor) in Combination With Endocrine Therapy in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT01791478
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:26:22.087029+00:00
- Published At
- 2024-07-23T00:00:00+00:00
- Record Updated At
- 2024-07-23
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Estrogen Receptor-positive Breast Cancer", "HER2-negative Breast Cancer", "Invasive Ductal Breast Carcinoma", "Progesterone Receptor-positive Breast Cancer", "Recurrent Breast Cancer", "Stage IV Breast Cancer"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-07-23"- protocolSection.identificationModule.nctId
"NCT01791478"- protocolSection.identificationModule.officialTitle
"A Phase Ib Trial of BYL719 (an \u03b1-Specific PI3K Inhibitor) in Combination With Endocrine Therapy in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.